Klaria Pharma outlines European rollout of migraine treatment

Klaria Pharma Holding AB has detailed its commercial strategy for its migraine treatment, Sumatriptan Alginate Film (SAF), following an interview with Chairman Fredrik Hübinette. The company anticipates a boost in revenue through milestone payments and royalties as its license partner, CNX Therapeutics, initiates the European market launch.

The pharmaceutical firm is positioning the product to compete in the established migraine treatment sector. While European operations are the immediate priority, the company is concurrently evaluating expansion strategies for the U.S. market. Klaria has engaged BDO to assist in navigating the regulatory and commercial frameworks required for such an entry.

Klaria’s financial outlook for the coming 12 months remains tied to the success of these distribution agreements. The firm currently focuses on the transition from a development-stage entity to a provider with recurring royalty streams.